| Serum thrombopoietin compared with ZAP-70 and immunoglobulin heavy-chain gene mutation status as a predictor of time to first treatment in early chronic lymphocytic leukemia. | |
| | |
MedLine Citation:
|
PMID: 18203013 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
In an effort to confirm previous reports we analyzed clinico-biological implications of increased serum levels of thrombopoietin (TPO) in a series of 71 previously untreated Binet stage A B-cell chronic lymphocytic leukemia (CLL) patients. Serum levels of TPO did not correlate with peripheral blood lymphocytosis (p = 0.928), Rai substages (p = 0.516), platelet count (p = 0.572), hemoglobin level (p = 0.228), LDH (p = 0.144) and beta2-microglobulin (p = 0.520). The same applied when correlation with ZAP-70 (p = 0.562), CD38 (p = 0.258) or mutational status of IgV(H) (p = 0.0794) were sought. The risk of disease-progression according to known and putative prognostic parameters was also evaluated as time to first treatment (TFT). The univariate Cox proportional hazard model demonstrated that the absence of IgV(H) mutational status (p = 0.0005) and ZAP-70-positivity (p = 0.02) were associated with a shorter TFT. In contrast, Kaplan-Meier estimates of TFT, plotted after setting as cut-off the median value for TPO (i.e., 46 pg/mL), failed to demonstrate any statistical difference between two groups (p = 0.342). Looking for cellular source of TPO we investigated the presence of TPO at gene expression level in 60 B-CLL patients belonging to an independent series. Here we provide evidence for the presence of a low TPO gene expression transcript in B-CLL cells. In conclusion, our results indicate that in early B-cell CLL circulating level of TPO does not provide a useful insight into the complex interrelationship of prognostic variables. |
| | |
Authors:
|
Stefano Molica; Gaetano Vitelli; Giovanna Cutrona; Katia Todoerti; Rosanna Mirabelli; Giovanna Digiesi; Fortunato Morabito; Antonino Neri; Manlio Ferrarini |
Related Documents
:
|
3877853 - Lymphocytotoxic t lymphocytes in a patient with b-chronic lymphocytic leukemia and pure... 7620163 - Antigen receptor nonresponsiveness in chronic lymphocytic leukemia b cells. 6472513 - Derivatives of benzo(c)fluorene. xi. effect of benfluron on hemopoietic stem cells. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Leukemia & lymphoma Volume: 49 ISSN: 1029-2403 ISO Abbreviation: Leuk. Lymphoma Publication Date: 2008 Jan |
Date Detail:
|
Created Date: 2008-01-18 Completed Date: 2008-04-16 Revised Date: 2012-06-05 |
Medline Journal Info:
|
Nlm Unique ID: 9007422 Medline TA: Leuk Lymphoma Country: England |
Other Details:
|
Languages: eng Pagination: 62-7 Citation Subset: IM |
Affiliation:
|
Department of Oncology/Hematology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy. smolica@libero.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Female Genes, Immunoglobulin Heavy Chain / genetics* Humans Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis* Middle Aged Mutation Predictive Value of Tests* Prognosis RNA, Messenger / blood Thrombopoietin / blood*, genetics ZAP-70 Protein-Tyrosine Kinase / blood* |
| Chemical | |
Reg. No./Substance:
|
0/RNA, Messenger; 9014-42-0/Thrombopoietin; EC 2.7.10.2/ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2/ZAP70 protein, human |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome.
Next Document: Phase II study of low-grade non-Hodgkin lymphomas with fludarabine and mitoxantrone followed by ritu...